Overall verdict
Sell
2.3/10
1-year performance
+19.16%
Score breakdown
Up 19.2% over 1 year, 45% of the 52-week range.
Strongest: Financial strength 8.8/10. Weakest: Shareholder return 0.0/10.
7 analysts, target +1.1% vs the price.
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases ; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease ;
and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions.
It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Arnon Rosenthal
Founded
2013
Employees
103
Revenue / employee
204 320 USD
Next earnings
November 6, 2026 (estimated)
Institutional holders
- TCG Crossover Management, LLC6.75%
- BlackRock, Inc.5.29%
- ACADIAN ASSET MANAGEMENT LLC2.98%
- Nantahala Capital Management, LLC2.91%
- VANGUARD CAPITAL MANAGEMENT LLC2.70%
- Kynam Capital Management, LP2.57%
- Merck & Co., Inc.2.39%
- Balyasny Asset Management L.P.2.19%
- 683 Capital Management, LLC2.16%
- Other institutions31.60%
- Rest of the register38.46%
139 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
2.76 USD
52-week low
1.09 USD
1-year performance
19.16%
Rising
Year-to-date performance
16.88%
Rising
Drawdown
-33.51%
Major drawdown
Position in the 52-week range
45% of range
Gross margin 37.1%, the company loses 850.1% of its revenue, ROIC -223.5%, ROE -385.1%.
Net margin
-850.13%
Negative
Sector -223.73%|S&P 13.15%
Gross margin
37.07%
Fair
Return on equity (ROE)
-385.11%
Negative
Sector -58.62%|S&P 16.61%
Return on invested capital (ROIC)
-223.46%
Negative
Free cash flow margin (FCF)
-1142.55%
Negative
Margin stability
1022.4 pts
Very uneven
Revenue to net income
Growth
0.0/10Revenue down 57.8% over 1 year, -0.1% a year over 5.
Revenue (trailing 12 months)
13.9M USD
Revenue growth (1y)
-57.84%
Declining
Revenue growth (3y)
-84.25%
Declining
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.4x|S&P 24.1x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 14.4x|S&P 15.2x
PEG
—
Sector -0.03|S&P 0.90
Market cap
272M USD
Financial strength
8.8/10Cash covers 527.5% of the debt, net debt/EBITDA 1.3x.
Net debt / EBITDA
1.3x
Solid
Gearing (net debt / equity)
—
Cash
173M USD
Cash / market cap
63.52%
Very solid
Cash / total debt
527.50%
Net cash
Net debt
-140M USD
Equity
-10.0M USD
Closed daily candles, 2 years
Last close on October 21, 2026: 1.87 USD
- MM201.92
- MM502.10
- MM2002.02
- RSI 1445.5
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+2.73%
200-day average slope, 3 months
+4.88%
50-day average slope, 1 month
+7.64%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
4.89 % per day
Volatility change
-10.45%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -0.45 (6) | -0.50 (5) | 66 (7) | -55 (2) | -51 (6) |
| 2027 | -0.84 (6) | -0.73 (5) | 11 (7) | -113 (2) | -111 (6) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of October 14, 2026.
Same sub-industry: 781 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AGEN | 5.6 | 4.9 | 289M USD | 2.4x | 69.3 % | 34.4 % | -11.7 % | 6.7x | -34.1 % | 44.8 % | ||
| 2 | SRZN | 5.5 | 4.3 | 298M USD | Not meaningful (loss) | -3042.9 % | 408.6 % | — | 2.2x | -11.8 % | 87.6 % | ||
| 3 | 6915 | 4.9 | 4.9 | 285M USD | — | — | 6.7 % | — | -0.7x | — | -7.8 % | ||
| 4 | PRLD | 4.7 | 3.5 | 291M USD | Not meaningful (loss) | -269.7 % | 73.4 % | -50.5 % | 2.0x | -11.4 % | 182.9 % | ||
| 5 | BNTC | 4.4 | N/A | 297M USD | Not meaningful (loss) | — | — | -33.1 % | 3.5x | -5.9 % | -46.2 % | ||
| 6 | NWBO | 3.5 | 4.0 | 281M USD | Not meaningful (loss) | -1736.4 % | 535.4 % | 275.6 % | -1.3x | -17.7 % | -25.0 % | ||
| 7 | IPSC | 3.4 | 1.5 | 292M USD | Not meaningful (loss) | -100.6 % | 1556.8 % | -41.9 % | 0.9x | -30.2 % | 182.2 % | ||
| 8 | XFOR | 3.2 | 3.0 | 298M USD | Not meaningful (loss) | -568.8 % | 346.3 % | -57.6 % | 1.5x | — | -4.4 % | ||
| 9 | ALEC | 2.3 | 1.3 | 272M USD | Not meaningful (loss) | -850.1 % | -57.8 % | -223.5 % | 1.3x | -58.2 % | 19.2 % |
